PTH-068 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series

IntroductionThe relative risk for tuberculosis (TB) can increase by ≤25 times with anti-tumour necrosis factor-alpha (TNFα) therapy.1 Vedolizumab (VDZ) is a humanised monoclonal antibody that targets α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Gut selectivity may be ass...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gut 2017-07, Vol.66 (Suppl 2), p.A240
Hauptverfasser:	Zerôncio, M, Blake, A, Rana-Khan, Q, Palo, W, Bhayat, F
Format:	Artikel
Sprache:	eng
Schlagworte:	Biotechnology Clinical trials Crohn's disease Immunosuppression Inflammatory bowel disease Marketing Monoclonal antibodies Parathyroid hormone Patients Pharmacology Tuberculosis Tumor necrosis factor-α Tumors Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!